SEARCH

SEARCH BY CITATION

References

  • 1
    Boring CC, Squires TS, Tong T: Cancer Statistics: 1993. CA Cancer J Clin 1993; 43: 726.
  • 2
    Stenzl A, deKernion JB: Pathology, biology, and clinical staging of renal cell carcinoma. Semin Oncol 1989; 16 (suppl 1): 311.
  • 3
    Bloom HJ: Hormone-induced and spontaneous regression of metastatic renal cancer. Cancer 1973; 32: 10661071.
  • 4
    Yagoda A: Chemotherapy of renal cell carcinoma:1983–1989. Semin Urol 1989; 7: 199206.
  • 5
    Montie JE, Stewart BH, Straffon RA, et al: The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977; 117: 272275.
  • 6
    de Riese W, Allhoff E, Kirchner H, et al: Complete spontaneous regression in metastatic renal cell carcinoma: An update and review. World Journal of Urology 1991: 9: 184191.
  • 7
    Quesada JR, Rios A, Swanson D, et al: Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985; 3: 15221528.
  • 8
    Figlin RA, deKernion JB, Mukamel E, et al: Recombinant interferon alfa-2a in metastatic renal cell carcinoma: Assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol 1988; 6: 16041610.
  • 9
    Muss HB: Interferon therapy of metastatic renal cell cancer. Sem Surg Oncol 1988; 4: 199203.
  • 10
    Balkwill FR, Moodie EM: Positive interactions between human interferon and cyclophosphamide or Adriamycin in a human tumor model system. Cancer Res 1984; 44: 904908.
  • 11
    Dexeus FH, Logothetis CJ, Sella A, Finn L: Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma. Am J Clin Oncol 1989; 12: 350354.
  • 12
    Sella A, Logothetis CJ, Fitz K, et al: Phase II study of interferon-α and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J Urol 1992; 147: 573577.
  • 13
    Bergerat JP, Herbrecht R, Dufour P, et al: Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer. Cancer 1988; 62: 23202324.
  • 14
    Neidhart JA, Anderson SA, Harris JE, et al: Vinblastine fails to improve response of renal cancer to interferon alfa-n1: High response rate in patients with pulmonary metastases. J Clin Oncol 1991; 9: 832836.
  • 15
    Schornagel JH, Verweij J, ten Bokkel Huinink WW, et al: Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma. J Urol 1989; 142: 253256.
  • 16
    Sertoli MR, Brunetti I, Ardizzoni A, et al: Recombinant α-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. Am J Clin Oncol 1989; 12: 4345.
  • 17
    Fossa SD, Stenwig AE, Lien HH: Long-term results in patients with metastatic renal cell carcinoma treated with interferon with or without vinblastine. World Journal of Urology 1991; 9: 210214.
  • 18
    Fossa SD, Gunderson R, Moe B: Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Cancer 1990; 65: 24512454.
  • 19
    Aulitzky W, Gastl G, Aulitzky WE, et al: Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 1989; 7: 18751884.
  • 20
    Grups JW, Frohmüller HGW: Cyclic interferon gamma treatment of patients with metastatic renal carcinoma. Br J Urol 1989; 64: 218220.
  • 21
    Garnick MB, Reich SD, Maxwell B, et al: Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma. J Urol 1988; 139: 251255.
  • 22
    Bruntsch U, de Mulder PHM, ten Bokkel Huinink WW, et al: Phase II study of recombinant human interferon-γ in metastatic renal cell carcinoma. J Biol Response Mod 1990; 9: 335338.
  • 23
    de Mulder PHM, Debruyne FMJ, Franssen MPH, et al: Phase I/II study of recombinant interferon and in advanced progressive renal-cell carcinoma. Cancer Immunol Immunother 1990; 31: 321324.
  • 24
    Ernstoff MS, Nair S, Bahnson RR, et al: A phase IA trial of sequential administration recombinant DNA-produced interferons: Combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 1990; 8: 16371649.
  • 25
    Morgan DA, Ruscetti FW, Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 10071008.
  • 26
    Mulé JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 14871489.
  • 27
    Rosenberg SA, Lotze MT, Yang JC, et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474485.
  • 28
    Rosenberg SA: Adoptive cellular therapy in patients with advanced cancer: An update. Biologic Therapy of Cancer Updates 1991; 1: 115.
  • 29
    Robertson CN, Linehan WM, Pass HI, et al: Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 1990; 144: 614618.
  • 30
    Spencer WF, Linehan WM, Walther MM, et al: Immunotherapy with interleukin-2 and α-interferon in patients with metastatic renal cell cancer with in situ primary cancers: A pilot study. J Urol 1992; 147: 2430.
  • 31
    Belldegrun A, Figlin R, Haas GP, deKernion JB: Immunotherapy for metastatic renal-cell carcinoma. World J Urol 1991; 9: 157159.
  • 32
    Package Insert for Proleukin, Cetus Oncology Corporation. May 1992.
  • 33
    Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137: 17351742.
  • 34
    Siegel JP, Puri RK: Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694704.
  • 35
    Margolin KA, Rayner AA, Hawkins MJ, et al: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989; 7: 486498.
  • 36
    Sosman JA, Kohler PC, Hank J, et al: Repetitive weekly cycles of recombinant human interleukin-2: Responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 1988: 80: 6063.
  • 37
    West WH, Tauer KW, Yannelli JR, et al: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898905.
  • 38
    Weiss GR, Margolin KA, Aronson FR, et al: A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992; 10: 275281.
  • 39
    Whitehead RP, Ward D, Hemingway L, et al: Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res 1990; 50: 67086715.
  • 40
    Huland E, Huland H, Heinzer H: Interleukin-2 by inhalation: Local therapy for metastatic renal cell cancer. J Urol 1992; 147: 344348.
  • 41
    Skillings J, Wierzbicki R, Eisenhauer E, et al: A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. J Immunotherapy 1992; 11: 6770.
  • 42
    Kirchner H, de Riese W, Allhoff E, et al: Immunotherapy of advanced renal cell cancer using subcutaneous recombinant interleukin-2 and interferon-alpha. World Journal of Urology 1991; 9: 219222.
  • 43
    Pomer S, Thiele R, Daniel V, et al: Sequential treatment of patients with advanced renal cell carcinoma with autologous tumor vaccine and subcutaneous administration of recombinant interleukin-2 and interferon alpha2b. World Journal of Urology 1991; 9: 223227.
  • 44
    Redman BG, Flaherty L, Chou TH, et al: A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer. J Clin Oncol 1990; 8: 12691276.
  • 45
    Baars JW, Wagstaff J, Boven E, et al: Phase I study on the sequential administration of recombinant human interferon-γ and recombinant human interleukin-2 in patients with metastatic solid tumors. J Natl Cancer Inst 1991; 83: 14081410.
  • 46
    Sherry RM, Rosenberg SA, Yang JC: Relapse after response to interleukin-2-based immunotherapy: Patterns of progression and response to retreatment. J Immunotherapy 1991; 10: 371375.
  • 47
    Rosenberg SA, Speiss P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 13181321.
  • 48
    Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 16761680.
  • 49
    Kradin RL, Kurnick JT, Lazarus DS, et al: Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989; 8638: 577580.
  • 50
    Bukowski RM, Sharfman W, Murthy S, et al: Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res 1991; 51: 41994205.
  • 51
    Hayakawa K, Salmeron MA, Parkinson DR, et al: Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: Sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. J Immunotherapy 1991; 10: 313325.
  • 52
    Yoshizawa H, Chang AE, Shu S: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991; 147: 729737.
  • 53
    Osband ME, Lavin PT, Babayan RK, et al: Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 1990; 335: 994998.
  • 54
    Rosenberg SA, Aebersold P, Cornetta K, et al: Gene transfer into humans: Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570578.
  • 55
    Chiou RK, Grand FM, Vesella RL, et al: Phase I-II clinical trial of radioimmunoscintigraphy (RIS) and monoclonal antibody (Mab)-targeted radiotherapy for renal cell carcinoma (RCC). J Urol 1988; 139: 293A.